Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 25 2 2020
medline: 22 10 2020
entrez: 25 2 2020
Statut: ppublish

Résumé

Eosinophilic renal neoplasms have a wide spectrum of histologic presentations, and several studies have demonstrated a subtype of renal cell carcinomas (RCCs) associated with the tuberous sclerosis complex (TSC)/mammalian target of rapamycin pathway. A review of our institutional archives led to the identification of 18 cases of renal eosinophilic tumors with unusual morphology. Immunohistochemical analysis demonstrated that these could be separated into 3 groups: group 1 had solid architecture and morphology similar to chromophobe RCC but was negative for CK20 and vimentin, and had weak focal staining for CK7 and P504S; group 2 had solid architecture and morphology similar to either renal oncocytoma or chromophobe RCC, eosinophilic variant and had diffuse staining of CK7 and P504S, absent to weak staining of CK20, and negative staining for vimentin; and group 3 had solid, cystic and papillary architecture and was negative for CK7, except for 1 case, along with moderate to strong staining of CK20, P504S, and vimentin. The cases were then sent for next-generation sequencing to determine whether molecular pathogenic variants were present. In group 1, all 3 cases had mutations in TSC2. In group 2, pathogenic variants were identified in 3 genes: TSC1, TSC2, and MTOR. In group 3, genetic alterations and pathogenic variants were identified in TSC1 and TSC2. Our results support TSC/MTOR-associated neoplasms as a distinct group that exhibits heterogenous morphology and immunohistochemical staining.

Identifiants

pubmed: 32091432
doi: 10.1097/PAS.0000000000001457
pii: 00000478-202007000-00015
doi:

Substances chimiques

Biomarkers, Tumor 0
TSC1 protein, human 0
TSC2 protein, human 0
Tuberous Sclerosis Complex 1 Protein 0
Tuberous Sclerosis Complex 2 Protein 0
MTOR protein, human EC 2.7.1.1
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

943-954

Références

Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84.
International Agency for Research on Cancer. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: WHO/IARC Press; 2016.
Perrino CM, Grignon DJ, Williamson SR, et al. Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. Histopathology. 2018;72:305–319.
Kryvenko ON, Jorda M, Argani P, et al. Diagnostic approach to eosinophilic renal neoplasms. Arch Pathol Lab Med. 2014;138:1531–1541.
Guo J, Tretiakova MS, Troxell ML, et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol. 2014;38:1457–1467.
Yang P, Cornejo KM, Sadow PM, et al. Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol. 2014;38:895–909.
Trpkov K, Hes O, Bonert M, et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40:60–71.
Trpkov K, Abou-Ouf H, Hes O, et al. Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol. 2017;41:1299–1308.
Chen Y-B, Mirsadraei L, Jayakumaran G, et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43:121–131.
Palsgrove D, Li Y, Pratilas C, et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor tsc mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol. 2018;42:1166–1181.
Parilla M, Kadri S, Patil S, et al. Are sporadic eosinophilic solid and cystic renal cell carcinomas characterized by somatic tuberous sclerosis gene mutations? Am J Surg Pathol. 2018;42:911–917.
Mehra R, Vats P, Cao X, et al. Somatic bi-allelic loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma. Eur Urol. 2018;74:483–486.
Parilla M, Kadri S, Patil SA, et al. Integrating a large next-generation sequencing panel into the clinical diagnosis of gliomas provides a comprehensive platform for classification from FFPE tissue or smear preparations. J Neuropathol Exp Neurol. 2019;78:257–267.
Talevich E, Shain AH, Botton T, et al. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12:e1004873.
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
Wobker SE, Williamson SR. Modern pathologic diagnosis of renal oncocytoma. J Kidney Cancer VHL. 2017;4:1–12.
Ng KL, Morais C, Bernard A, et al. A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma. J Clin Pathol. 2016;69:661–671.
Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26:319–330.
Shen SS, Truong LD, Scarpelli M, et al. Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? Arch Pathol Lab Med. 2012;136:410–417.
Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15:1162–1169.
Ricketts CJ, De Cubas AA, Fan H, et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:313.e5–326.e5.
Mete O, van der Kwast TH. Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intra-abdominal neoplasms. Arch Pathol Lab Med. 2011;135:665–670.
Tretiakova MS. Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid angiomyolipoma: series of 4 primary tumors and 2 metastases. Hum Pathol. 2018;80:65–75.
Brimo F, Robinson B, Guo C, et al. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol. 2010;34:715–722.
Huang K-H, Huang C-Y, Chung S-D, et al. Malignant epithelioid angiomyolipoma of the kidney. J Formos Med Assoc. 2007;106:S51–S54.
Kawaguchi K, Oda Y, Nakanishi K, et al. Malignant transformation of renal angiomyolipoma: a case report. Am J Surg Pathol. 2002;26:523–529.
Ma L, Kowalski D, Javed K, et al. Atypical angiomyolipoma of kidney in a patient with tuberous sclerosis: a case report with p53 gene mutation analysis. Arch Pathol Lab Med. 2005;129:676–679.
Pan C-C, Chung M-Y, Ng K-F, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol. 2008;214:387–393.
Malinowska I, Kwiatkowski DJ, Weiss S, et al. Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biologic distinction. Am J Surg Pathol. 2012;36:783–784.
Li Y, Reuter VE, Matoso A, et al. Re-evaluation of 33 “unclassified” eosinophilic renal cell carcinomas in young patients. Histopathology. 2018;72:588–600.
Hoogeveen-Westerveld M, Wentink M, van den Heuvel D, et al. Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex. Hum Mutat. 2011;32:424–435.
Coevoets R, Arican S, Hoogeveen-Westerveld M, et al. A reliable cell-based assay for testing unclassified TSC2 gene variants. Eur J Hum Genet. 2009;17:301–310.
Hung C-C, Su Y-N, Chien S-C, et al. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. BMC Med Genet. 2006;7:72.
Avgeris S, Fostira F, Vagena A, et al. Mutational analysis of TSC1 and TSC2 genes in tuberous sclerosis complex patients from Greece. Sci Rep. 2017;7:1–9.
Grabiner BC, Nardi V, Birsoy K, et al. A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014;4:554–563.
Yang H, Rudge DG, Koos JD, et al. mTOR kinase structure, mechanism and regulation. Nature. 2013;497:217–223.
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–366.
Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016;22:2445–2452.
Sakamoto H, Yamasaki T, Sumiyoshi T, et al. A family case with germline TSC1 and mtDNA mutations developing bilateral eosinophilic chromophobe renal cell carcinomas without other typical phenotype of tuberous sclerosis. J Clin Pathol. 2018;71:936–943.

Auteurs

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH